TY - JOUR
T1 - The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study
AU - Mekinian, Arsène
AU - Lazzaroni, Maria Grazia
AU - Kuzenko, Anna
AU - Alijotas-Reig, Jaume
AU - Ruffatti, Amelia
AU - Levy, Pierre
AU - Canti, Valentina
AU - Bremme, Katarina
AU - Bezanahary, Holy
AU - Bertero, Tiziana
AU - Dhote, Robin
AU - Maurier, Francois
AU - Andreoli, Laura
AU - Benbara, Amélie
AU - Tigazin, Ahmed
AU - Carbillon, Lionel
AU - Nicaise-Roland, Pascale
AU - Tincani, Angela
AU - Fain, Olivier
PY - 2015/1/1
Y1 - 2015/1/1
N2 - © 2015 Elsevier B.V. In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS.We analyzed the outcome of pregnancies treated by hydroxychloroquine in patients with APS or asymptomatic antiphospholipid (aPL) antibodies carriers.Thirty patients with APS with 35 pregnancies treated by hydroxychloroquine were analyzed. Comparing the outcome of pregnancies treated by the addition of hydroxychloroquine to previous pregnancies under the conventional treatment, pregnancy losses decreased from 81% to 19% (p. <. 0.05), without differences in the associated treatments. The univariate analysis showed that the previous intrauterine deaths and higher hydroxychloroquine amount (400. mg per day) were the factors associated with pregnancy outcome. Considering 14 patients with previous refractory obstetrical APS (n. =. 5 with obstetrical and thrombotic primary APS and n. =. 9 with purely obstetrical APS), all with previous pregnancy losses under treatment (aspirin with LMWH in 11 cases and LMWH in 3 cases), the addition of hydroxychloroquine resulted in live born babies in 11/14 (78%) cases (p. <. 0.05).Our study shows the benefit of hydroxychloroquine addition in patients with refractory obstetrical APS and raises the need of prospective studies to confirm our preliminary study.
AB - © 2015 Elsevier B.V. In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS.We analyzed the outcome of pregnancies treated by hydroxychloroquine in patients with APS or asymptomatic antiphospholipid (aPL) antibodies carriers.Thirty patients with APS with 35 pregnancies treated by hydroxychloroquine were analyzed. Comparing the outcome of pregnancies treated by the addition of hydroxychloroquine to previous pregnancies under the conventional treatment, pregnancy losses decreased from 81% to 19% (p. <. 0.05), without differences in the associated treatments. The univariate analysis showed that the previous intrauterine deaths and higher hydroxychloroquine amount (400. mg per day) were the factors associated with pregnancy outcome. Considering 14 patients with previous refractory obstetrical APS (n. =. 5 with obstetrical and thrombotic primary APS and n. =. 9 with purely obstetrical APS), all with previous pregnancy losses under treatment (aspirin with LMWH in 11 cases and LMWH in 3 cases), the addition of hydroxychloroquine resulted in live born babies in 11/14 (78%) cases (p. <. 0.05).Our study shows the benefit of hydroxychloroquine addition in patients with refractory obstetrical APS and raises the need of prospective studies to confirm our preliminary study.
KW - Hydroxychloroquine
KW - Obstetrical antiphospholipid syndrome
KW - Outcome
U2 - 10.1016/j.autrev.2015.01.012
DO - 10.1016/j.autrev.2015.01.012
M3 - Review article
SN - 1568-9972
VL - 14
SP - 498
EP - 502
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 6
ER -